EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 1-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION
Abstract: OP0144
Authors: A. Deodhar et al.
Key content:
Upadacitinib has been shown to be effective in the treatment of AS vs placebo at 14 weeks. The placebo patients were switched to Upa 15mg/d and all patients continued in a 90 week open-label extension phase. This abstract presents the 1 year results of the SELECT AXIS-1 study of Upadacitinib. At week 64, 85% of the patients that continued Upa had reached ASAS40. The patients that switched at week 14 from placebo to Upa achieved ASAS40 in 81%. There were low rates of serious adverse events and adverse events leading to discontinuation, in particular no serious infections and no thromboembolic events occurred. No unexpected or new AEs were noted.
Relevance:
This study shows sustained efficacy of the JAK1 selective inhibitor Upadacitinib for the treatment of AS. Such studies are the basis to establish JAK inhibition as a therapeutic option to treat AS.
